Safety and Efficacy of MSC-EVs in the Prevention of BPD in Extremely Preterm Infants

Last updated: September 9, 2024
Sponsor: EXO Biologics S.A.
Overall Status: Active - Recruiting

Phase

1/2

Condition

Lung Disease

Treatment

Endotracheopulmonary Instillation, Suspension

Clinical Study ID

NCT06279741
EVENEW
2022-500293-34
U1111-1291-0283
  • Ages < 10
  • All Genders

Study Summary

The phase 1/2 trial aims to evaluate the safety and efficacy of EXOB-001 consisting of extracellular vesicles derived from umbilical cord mesenchymal stromal cells in the prevention of bronchopulmonary dysplasia (BPD) in extremely premature neonates. The study population includes babies born between 23 and 28 (27 + 6 days) weeks of gestational age and body weight between 500g and 1,500 g. Thirty-six subjects will receive one or three administrations of the three doses of EXOB-001 via the endotracheal route in phase 1. In phase 2, two dosages based on the results of phase 1 will be selected and a total of 203 subjects will be randomised to receive either EXOB-001 or placebo (saline solution).

Infants will be followed up to 2 years of corrected age (end of study).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • From birth up to 10 days chronological age.

  • From 23 weeks up to 28 weeks (27 week+6 days) gestational age at birth.

  • Birth weight ≥ 500g but ≤1500g.

  • Endotracheally intubated and receiving mechanical ventilation with FiO2 > 25%anytime between 3 and 10 days postnatally or needing re-intubation due torespiratory complications, - Not expected to be extubated within the next 24/48hours after enrolment.

  • Written informed consent from parents/legally designated representative.

Exclusion

Exclusion Criteria:

  • Surfactant administration less than 24 hours prior to (first) IMP administration.

  • Has a congenital heart defect, except for patent ductus arteriosus (PDA), atrialseptal defect or a small/moderate, restrictive ventricular septal defect.

  • Has a serious malformation of the lung, such as pulmonary hypoplasia/aplasia,congenital diaphragmatic hernia, or any other congenital lung anomaly.

  • Being treated with inhaled nitric oxide.

  • Has a known chromosomal abnormality (e.g., Trisomy 18, Trisomy 13, or Trisomy 21) ora severe congenital malformation (e.g., hydrocephalus and encephalocele,trachea-oesophageal fistula, abdominal wall defects, and major renal anomalies).

  • Has had a known severe congenital infectious disease (i.e., herpes, toxoplasmosisrubella, syphilis, human immunodeficiency virus, cytomegalovirus, etc.).

  • Active systemic infection, severe sepsis, or septic shock at Screening up tobaseline (phase I) or randomization (phase II).

  • Underwent a surgical procedure (requiring admission to an operating room) within 72hours before baseline (phase I)/randomization (phase II) or who is anticipated tohave a surgical procedure (requiring admission to an operating room) within 72 hoursbefore or following baseline (phase I)/randomization (phase II).

  • Has had a Grade 3 or 4 intraventricular haemorrhage (IVH).

  • Has active pulmonary haemorrhage.

  • Has periventricular leukomalacia (PVL).

  • The subject is currently participating in any other interventional clinical study.

  • The subject is, in the opinion of the Investigator, so ill that death is inevitable,or is considered inappropriate for the study such as an infant that receivedthoracic compressions and/or adrenaline administration during stabilization in thedelivery room and for any reason(s) other than those listed above.

Study Design

Total Participants: 265
Treatment Group(s): 1
Primary Treatment: Endotracheopulmonary Instillation, Suspension
Phase: 1/2
Study Start date:
December 28, 2023
Estimated Completion Date:
December 31, 2029

Study Description

Bronchopulmonary Dysplasia (BPD) is a chronic severe multifactorial respiratory disease that affects extremely premature infants and is the most common and severe consequence of preterm birth. BPD is associated with disrupted alveolarization and microvascular development, resulting in abnormal gas exchange and lung mechanics. BPD has a multifactorial aetiology, with pre-, peri-, and postnatal mechanisms causing inflammation and injury and resulting in the disruption of the lung's development with the insurgence of an aberrant repair mechanism.

EXOB-001 consists of a population of EVs smaller than 0.22 μm in diameter, containing proteins and nucleic acids, enclosed in a double layer of phospholipids with integral and surface-bound proteins as the main components. EVs exert anti-inflammatory and immunomodulatory activity by reducing the release of proinflammatory cytokines and reducing the recruitment of immune cells in the lung. Current evidence shows that EVs can modulate macrophage phenotype, and this is relevant for BPD, because of the role macrophages have in its pathogenesis.

Two hundred sixty-five (265), 40 in phase 1 (to reach 36 evaluable subjects) + 225 in phase 2 (to reach 203 evaluable subjects), extremely preterm infants at risk of developing BPD with 23 weeks up to 28 (27 weeks+6 days) weeks of gestational age and birth weight between 500g and 1,500g and being endotracheally intubated between postnatal day 3 and day 10 receiving mechanical ventilation with FiO2 > 25%.

Phase 1 will start with cohorts with a single administration starting with a low dose up to a high dose and thereafter start the escalation of cohorts with 3 administrations starting with a low dose up to a high dose. In the case of 3 endotracheal administrations, there will be a window of 24 hours between the administrations (the maximal duration of the treatment with EXOB-001 will be 48 hours).

Phase 2 includes 2 groups with selected dosage levels and regimen of EXOB-001 based on phase 1 interim results. Subjects will be randomised (2:2:1) to receive either EXOB-001 or placebo (saline solution).

Connect with a study center

  • Cliniques Universitaires Saint-Luc (UCLouvain)

    Brussels, 1200
    Belgium

    Site Not Available

  • ISPPC CHU Charleroi

    Charleroi, 6000
    Belgium

    Site Not Available

  • Clinique CHC Montlégia

    Liège, 4000
    Belgium

    Site Not Available

  • AOU Careggi

    Florence,
    Italy

    Site Not Available

  • IRCCS Instituto Giannina Gaslini

    Genova,
    Italy

    Active - Recruiting

  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

    Milan,
    Italy

    Site Not Available

  • AOU Policlinico di Modena

    Modena,
    Italy

    Site Not Available

  • Unità di Fase I della UOC Terapia Intensiva e Patologia Neonatale, Assistenza Neonatale (TINI) dell'Azienda Ospedale Università di Padova

    Padua, 35128
    Italy

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.